C RAY THERAPEUTICS
C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020.
C RAY THERAPEUTICS
Industry:
Health Care Health Diagnostics Medical Nuclear
Founded:
2020-01-01
Status:
Active
Total Funding:
0
Investors List
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series A - C Ray Therapeutics
More informations about "C Ray Therapeutics"
C-Ray Therapeutics (Beijing) Co., Ltd. - Drug pipelines, Patents ...
Explore C-Ray Therapeutics (Beijing) Co., Ltd. with its drug pipeline, therapeutic area, technology platform, .See details»
C-Ray Therapeutics (Chengdu) Co., Ltd. - Drug pipelines, Patents ...
Explore C-Ray Therapeutics (Chengdu) Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Disease Domain:Neoplasms, Technology ...See details»
C Ray Secures $100M in Series A+ Financing for โฆ
Nov 19, 2024 Founded in 2021 and headquartered in Chengdu Medical City, C Ray Therapeutics focuses on innovative radiopharmaceutical solutions for oncology, โฆSee details»
C Ray Therapeutics $100M to improve RDC technology platform
Nov 19, 2024 Founded in late 2020, C Ray Therapeutics has rapidly established world-class facilities and expertise in R&D, production and supply chain management of โฆSee details»
C Ray Therapeutics | VentureRadar
C Ray Therapeutics specializes in the research, development, production, and clinical application of radiopharmaceuticals. The company has established advanced R&D platforms and โฆSee details»
C Ray Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Nov 17, 2024: Series A - C โฆSee details»
C Ray Therapeutics Completes Over $100 Million Series A
Nov 18, 2024 C Ray Therapeutics boasts unique advantages in the field of radiopharmaceutical R&D, including the ability to integrate and streamline the nuclear industry supply chain. The โฆSee details»
Chinese radiopharma firm C Ray raises over $100m Series A+
Nov 17, 2024 Chinese radiopharmaceutical startup C Ray Therapeutics announced on Saturday that it has raised over $100 million in a Series A+ funding round to strengthen its technology โฆSee details»
C Ray Therapeutics Completes Over $100M Series A+ Financing
Nov 18, 2024 C Ray Therapeutics, a Chengdu, China-based enterprise in the field of radiopharmaceuticals, raised over $100M in Series A+ funding. The round was led by โฆSee details»
C Ray Therapeutics - VentureRadar
Alys Pharmaceuticals Inc. Switzerland Privately Held Alys Pharmaceuticals is an immuno-dermatology focused company that combines the assets and platforms of Aldena โฆSee details»
C Ray Therapeutics ๏ผHK๏ผ Limited - Drug pipelines, Patents, โฆ
Explore C Ray Therapeutics ๏ผHK๏ผ Limited with its drug pipeline, therapeutic area, technology platform, . Data. Feature. Plans. Sign Up for Free. Request Demo. Sign Up for Free. Last โฆSee details»
C Ray Therapeutics Completes Over $100 Million Series A
CHENGDU, China, Nov. 18, 2024 /PRNewswire/ -- In November 2024, C Ray Therapeutics (Chengdu) Co., Ltd. (hereinafter referred to as โC Rayโ), an innovative enterprise in the field of โฆSee details»
Series A - C Ray Therapeutics - 2024-11-17 - Crunchbase
C Ray Therapeutics raised $100000000 on 2024-11-17 in Series A. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log In. โฆSee details»
C Ray Therapeutics Completes Series A+ Financing Round โฆ
Nov 18, 2024 C Ray Therapeutics (Chengdu) Co., Ltd. has completed a Series A+ financing round exceeding $100 million co-led by Shenzhen Capital Group Co., Ltd.'s Manufacturing โฆSee details»
C Ray Therapeutics Company Profile | Management and
Based in Chengdu, China, C Ray Therapeutics is a medtech company with a focus on radiopharmaceuticals. Popular Searches. C Ray Therapeutics. Primary Industries. Business โฆSee details»
C-Ray Therapeutics - PitchBook
Jul 30, 2021 C-Ray Therapeutics General Information Description. Developer and manufacturer of radiopharmaceuticals designed to treat tumors. The company's radiopharmaceutical is a โฆSee details»
C-Ray Therapeutics Secures Over $100 Million in A+ Round โฆ
Nov 16, 2024 C-Ray Therapeutics (Chengdu) Co., Ltd., an innovative enterprise in the field of radioactive medicines, has successfully completed over $100 million in A+ round financing. โฆSee details»
Series A - C Ray Therapeutics - 2021-07-30 - Crunchbase
Jul 30, 2021 Organization Name . C Ray Therapeutics . Announced Date Jul 30, 2021; Funding Type Series A; Funding Stage Early Stage Venture; Investors. Edit Investors Section. Number โฆSee details»
New insights into proteinโprotein interaction modulators in drug ...
2 days ago The c-Myc/Max interaction can be disrupted by two main therapeutic approaches of which the first involves inhibiting the c-Myc/Max PPI while the second exploits the stabilization โฆSee details»
177Lu-TR0471 - Drug Targets, Indications, Patents - Synapse
Nov 21, 2024 177Lu-TR0471, Initially developed by C-Ray Therapeutics (Chengdu) Co., Ltd., Now, its global highest R&D status is Phase 1, Therapeutic Areas: Neoplasms,Urogenital โฆSee details»